Marathon Asset Management Ltd reduced its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 13.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 363,371 shares of the company’s stock after selling 55,072 shares during the quarter. Johnson & Johnson comprises 1.6% of Marathon Asset Management Ltd’s portfolio, making the stock its 21st biggest holding. Marathon Asset Management Ltd’s holdings in Johnson & Johnson were worth $56,322,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. GW&K Investment Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $35,000. Dark Forest Capital Management LP boosted its holdings in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $45,000. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $52,000. 67.57% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,163 shares of company stock worth $7,928,856. Insiders own 0.20% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Stock Performance
JNJ stock opened at $169.91 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The company has a 50 day moving average price of $162.48 and a 200 day moving average price of $161.10. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The stock has a market capitalization of $441.55 billion, a PE ratio of 34.39, a price-to-earnings-growth ratio of 2.81 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The firm had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter in the previous year, the company posted $2.59 EPS. Johnson & Johnson’s revenue was up 6.3% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.76 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 5 Best Office REITs to Buy Now
- Airline Stocks: What They Are and How to Invest
- Camping World Slashes its Dividend but Should You Cut the Stock?
- How to Invest in Mining Stocks
- SoFi Downgraded: Here’s How To Still Make Money
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
